



CORRIGENDUM

Earlier Use of Long-Acting Injectable Paliperidone Palmitate Once-Monthly versus Oral Antipsychotics in Patients with Schizophrenia: An Integrated Patient-Level Meta Analysis of the PROSIPAL and PRIDE **Studies** [Corrigendum]

Sajatovic M, Doring M, Lopena OJ, et al. Neuropsychiatr Dis Treat. 2024;20:2227—2235.

The authors have advised that there is a data error in Table 2 on page 2233. Under 0-3 Years n = 516, PP1M n = 253 column, Injection site pain row, the data "2 (9.5%)" should read "24 (9.5%)". The correct Table 2 is as follows.

Table 2 Incidence of Treatment-Emergent Adverse Events

| | 0-3 Years n = 516 | | >3-5 Years n = 272 | | >5 Years n = 369 | |
|---|----------------------|----------------|-----------------------|----------------|---------------------|----------------|
| | PPIM n = 253 | OAP n = 263 | PPIM n = 138 | OAP n = 134 | PPIM n = 187 | OAP n = 182 |
| Patients who experienced ≥I TEAE, n (%) | 197 (77.9%) | 182 (69.2%) | 99 (71.7%) | 93 (69.4%) | 155 (82.9%) | 149 (81.9%) |
| TEAEs occurring in ≥10% of patients | | | | | | |
| Injection site pain | 24 (9.5%) | 0 | 11 (8.0%) | 0 | 31 (16.6%) | 0 |
| Nasopharyngitis | 14 (5.5%) | 15 (5.7%) | 14 (10.1%) | 6 (4.5%) | 12 (6.4%) | 13 (7.1%) |
| Weight increased | 47 (18.6%) | 46 (17.5%) | 17 (12.3%) | 22 (16.4%) | 24 (12.8%) | 13 (7.1%) |
| Akathisia | 21 (8.3%) | 14 (5.3%) | 6 (4.3%) | 10 (7.5%) | 20 (10.7%) | 14 (7.7%) |
| Headache | 27 (10.7%) | 20 (7.6%) | 16 (11.6%) | 16 (11.9%) | 14 (7.5%) | 15 (8.2%) |
| Anxiety | 21 (8.3%) | 15 (5.7%) | 6 (4.3%) | 8 (6.0%) | 20 (10.7%) | 17 (9.3%) |
| Insomnia | 30 (11.9%) | 34 (12.9%) | 17 (12.3%) | 9 (6.7%) | 36 (19.3%) | 21 (11.5%) |
| Schizophrenia | 21 (8.3%) | 27 (10.3%) | 9 (6.5%) | 9 (6.7%) | 9 (4.8%) | 16 (8.8%) |

Abbreviations: OAP, oral antipsychotic; PPIM, paliperidone palmitate once monthly; TEAE, treatment-emergent adverse event.

The authors apologize for this oversight.

Neuropsychiatric Disease and Treatment

Publish your work in this journal

Dovepress Taylor & Francis Group

Neuropsychiatric Disease and Treatment is an international, peer-reviewed journal of clinical therapeutics and pharmacology focusing on concise rapid reporting of clinical or pre-clinical studies on a range of neuropsychiatric and neurological disorders. This journal is indexed on PubMed Central, the 'PsycINFO' database and CAS, and is the official journal of The International Neuropsychiatric Association (INA). The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

Submit your manuscript here: https://www.dovepress.com/neuropsychiatric-disease-and-treatment-journal

https://doi.org/10.2147/NDT.S547665